Toxicity of antiestrogens

Breast Journal

Volumn 8, Issue 2, 2002, Pages 92-96

  Hirsimäki, Pirkko ^a   Aaltonen, Annukka ^a,b   Mäntylä, Eero ^c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Hormos Medical Ltd   (Finland)

^c Brion Scientific Ltd   (Finland)

Author keywords

Antiestrogen; Endometrial cancer; Raloxifen; Tamoxifen; Toremifene; Toxicity

Indexed keywords

ANTIESTROGEN; CYTOCHROME P450 ISOENZYME; DROLOXIFENE; FULVESTRANT; IDOXIFENE; POLYSTYRENE DERIVATIVE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ANEUPLOIDY; ANIMAL CELL; ARTICLE; CANCER RISK; CARCINOGENICITY; CLINICAL TRIAL; DNA SYNTHESIS; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; FEMALE; GENOTOXICITY; HIGH RISK POPULATION; HUMAN; LIVER CELL; METABOLIC ACTIVATION; MICRONUCLEUS; NONHUMAN; RAT; TOXICITY; UTERUS CANCER;

AGE FACTORS; ANIMALS; BREAST NEOPLASMS; CARCINOGENICITY TESTS; CARCINOGENS; CLINICAL TRIALS; DNA DAMAGE; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LIVER; MALE; MUTAGENICITY TESTS; MUTAGENS; OSTEOPOROSIS; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 0036121767     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2002.08204.x     Document Type: Article

References (40)

1. Selective estrogen receptor modulators (SERMs) in clinical practice
2. Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen
3. On the safety studies of the antiestrogens toremifene and tamoxifen
4. Safety assessment of tamoxifen and toremifene
5. The tamoxifen dilemma
6. Genotoxicity studies with the antiestrogen toremifene
7. Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats
8. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lyphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells)
9. Reduced genotoxicity of (D5-ethyl)-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen
10. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s
11. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats
12. Tamoxifen causes gene mutations in the livers of Lambda/lacI transgenic rats
13. Tamoxifen induces G:C→T:A mutations in the cII gene in the liver lambda/ lacI transgenic rats but not at 5′-CpG-3′ dinucleotide sequences as found in thelacI transgene
14. Studies on the genotoxicity of tamoxifen citrate in mouse bone marrow cells
15. Effects of tamoxifen feeding on metabolic activation of tamoxifen by the liver of Rhesus monkey: Does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer?
16. DNA binding of tamoxifen and its analogues: Identification of the tamoxifen-DNA adducts in rat liver
17. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens
18. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat
19. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats
20. A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats
21. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen
22. The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation
23. DNA adduct formation by tamoxifen and structurally-related compounds in rat liver
24. Induction of endometrial cancer by tamoxifen in the rat
25. The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene
26. Uterine carcinoma in mice treated neonatally with tamoxifen
27. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia
28. Tamoxifen
29. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group
30. Synthesis and antiestrogenic activity of diaryl thioether derivatives
31. Second cancers after adjuvant tamoxifen therapy for breast cancer
32. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
33. Theories of endometrial carcinogenesis: A multidisciplinary approach
34. Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology
35. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas
36. Mullerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer
37. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
38. Toxicity and early survival results of a prospective, randomized adjuvant trial comparing toremifene and tamoxifen in node-positive breast cancer
39. The effects of raloxifene on risk of breast cancer in postmenopausal women
40. Preventing postmenopausal osteoporosis: An update on raloxifene